Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 562 followers
Latest posts
Last updated about 23 hours ago
GSK presents data from its advancing liver pipeline at AASLD 2025
about 24 hours ago
21 abstracts highlight advances in the treatment of liver conditions, building from...
GSK delivers strong Q3 performance and upgrades 2025 guidance
11 days ago
Q3 2025 performance highlights
GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases
11 days ago
siRNA candidate EMP-012 in phase I for treatment of COPD.
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives Orphan Drug Designation in the EU
11 days ago
Regulatory designation based on encouraging early clinical data showing potential for GSK’227...
GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer
12 days ago
ADC complements GSK’s diverse pipeline in prostate cancer anchored by GSK’227, a...
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
16 days ago
Blenrep is the only anti-BCMA accessible in the community setting where 70%...
GSK announces positive pivotal phase III data for next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler
17 days ago
Data confirm therapeutic equivalence and comparable safety profile for Ventolin (salbutamol) containing...
Positive PIVOT-PO phase III data show tebipenem HBr’s potential as the first oral carbapenem antibiotic for patients with complicated urinary tract infections (cUTIs)
18 days ago
Data presented at IDWeek 2025 after study stopped early for efficacy
GSK’s Shingrix new prefilled syringe presentation receives positive CHMP opinion
18 days ago
Prefilled syringe offers a convenient ready-to-use administration option to healthcare professionals.
Global Fund welcomes renewed commitment from GSK and ViiV Healthcare to expand community-led health solutions with £6 million joint pledge ahead of 8th Replenishment
19 days ago
The Global Fund to Fight AIDS, Tuberculosis and Malaria today welcomed a...
ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir
24 days ago
Findings could help inform expectations and decision-making when initiating long-acting HIV injectables
GSK’s Shingrix approved in China for prevention of shingles in adults aged 18 and over who are at increased risk due to immunodeficiency or immunosuppression
25 days ago
Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) is the first and only...